ClinicalTrials.gg
CompletedNCT03489018FPCVUpdated Nov 12, 2024

The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants

A Phase 4 interventional study of PCV10 and PCV13 in Pneumococcal Infection, Streptococcus Pneumoniae Infection and Invasive Pneumococcal Disease, Protection Against, sponsored by London School of Hygiene and Tropical Medicine. Completed at 1 site in Kenya. Open to participants aged 6 Weeks to 8 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by London School of Hygiene and Tropical Medicine · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Sep 2022, 4 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,100
Allocation
Randomized
Ages
6 Weeks to 8 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.

Enrollment
3rd of 44
2,100 · median 328
Started
2019
with 1 other
Phase 4
11 of 44
none open now
Registered
30th of 44
by date

Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 11 in phase 4, and was the 30th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →

About 13-valent pneumococcal vaccine

13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 6 Weeks to 8 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections as a file.
02

Study summary

Before the introduction of pneumonia vaccines in 2000, between 700,000 - 1 million children died each year as a result of infection with the bacteria Streptococcus pneumoniae and the resulting diseases, namely, meningitis, sepsis and pneumonia. Most of the deaths were in Africa and Asia. Where the vaccines have been introduced, they have been highly effective and have already reduced disease. However, at 10 USD per child, they are not affordable to most low-income countries without financial support from Gavi, the Vaccine Alliance.

This project aims to assess whether lower doses of the two commercially available pneumonia vaccines can protect Kenyan infants as well as the full dose. The results could be used to increase the affordability of the pneumonia vaccine, and enable delivery of the vaccine to continue in the absence of Gavi support.

Read the detailed description

Background:

PCV is currently the most expensive vaccine in the routine immunisation schedule in Gavi-supported countries. This study aims to provide evidence which may enable a substantial decrease in the cost of PCV programmes, therefore increasing the sustainability of PCV programmes in low and middle income countries (LMICs). We propose to assess whether fractional (20% and 40%) doses of pneumococcal conjugate vaccine (PCV10 and PCV13) in a 2p+1 schedule (2 primary doses followed by a booster dose) induce non-inferior immunogenicity and effects on vaccine-serotype carriage when compared to the full dose. These lower doses could convert new 4-dose vials of PCVs into 10- or 20-dose vials, ready for immediate implementation in LMIC programmes.

Primary objective:

Non-inferior immunogenicity at 1-month post-boost (10 months of age). Non-inferiority will be reached if the lower CI around the ratio of geometric mean concentrations (GMC) of IgG (fractional/full dose) is >0.5 (i.e. the 2-fold criterion).

Secondary objectives:

Non-inferior immunogenicity at 1-month post-primary series (18 weeks of age). Non-inferiority will be achieved if the lower limit of the 95% confidence interval (CI) around the difference in the proportion of 'responders', children with IgG>=0.35 mcg/ml, (fractional dose group - full dose group) is >-10% for at least 8 of the 10 vaccine types in the PCV10 arms and at least 10 of the 13 vaccine types in the PCV13 arms.

The opsonophagocytic activity of the antibody response to 7 serotypes after full/ fractional doses at the 1-month post-boost time point.

The direct vaccine effectiveness of full/fractional doses of PCV13 against carriage of serotypes 6A and 19A, with primary analyses at 18 months of age and secondary analyses at 9 months of age.

The proportion of children with evidence of vaccine-serotype carriage by trial arm at 9 and 18 months of age.

The geometric mean concentration (GMC) of serotype-specific IgG after the primary series of the 2p+1 schedule, prior to boost, at 9 months of age.

The geometric mean concentration (GMC) of serotype-specific IgG after three doses of vaccine in a 2p+1 schedule at 18 months of age.

The carriage prevalence at 9 and 18 months of age and IgG concentrations at 4 weeks after the primary series after full dose of PCV10 in a 3p+0 schedule, and full/ fractional doses of PCV10/13 in a 2p+1 schedule.

Trial design:

A phase IV individually-randomised controlled trial of full or fractional (20% or 40%) doses of PCV10/ PCV13, given as a 3-dose schedule to infants: 2 doses at 6 and 14 weeks of age and a booster dose at 9 months (the 2p+1 schedule) or 3 full doses at 6, 10 and 14 weeks of age (the 3p+0 schedule).

At 6-8 weeks of age, 300 infants will be enrolled at random into each of the seven trial arms and followed until 18 months of age.

The seven trial arms:

A. Full dose PCV13 vaccination in a 2p+1 schedule. B. 40% fractional dose PCV13 vaccination in a 2p+1 schedule. C. 20% fractional dose PCV13 vaccination in a 2p+1 schedule. D. Full dose PCV10 vaccination in a 2p+1 schedule. E. 40% fractional dose PCV10 vaccination in a 2p+1 schedule. F. 20% fractional dose PCV10 vaccination in a 2p+1 schedule. G. Full dose PCV10 vaccination in a 3p+0 schedule. This arm would represent the current vaccine and schedule in the Kenyan routine immunisation programme and would act as an additional comparison arm.

Study procedures:

No study procedures will be conducted without prior parental informed consent. Participants in trial arms A-F will provide 3 or 5 blood samples in the course of the trial at enrolment, 4 weeks post-primary series (approximately 18 weeks of age) and 4 weeks post-boost (approximately 10 months of age); additionally a random selection of half the participants will contribute blood samples pre-boost (9 months of age) and at the last study visit (18 months of age).

Participants in trial arm G will provide 2 blood samples (at enrolment and at 4 weeks post-primary series (approximately 18 weeks of age).

All participants will provide 2 nasopharyngeal swabs at approximately 9 and 18 months of age and contribute safety data.

03

Conditions studied

  • Pneumococcal Infection
  • Streptococcus Pneumoniae Infection
  • Invasive Pneumococcal Disease, Protection Against

Keywords

  • Pneumococcal Vaccines;
  • Immunogenicity, Vaccine
  • 10-valent pneumococcal vaccine
  • 13-valent pneumococcal vaccine
  • Schedule
  • Pneumococcal Infection
  • Kenya
  • Infant
  • Vaccines, Conjugate
  • Humans
  • Immunization schedule
  • Streptococcus pneumoniae
  • vaccine
  • Dose-Response Relationship, immunologic
  • Equivalence Trial as Topic
04

Who can participate

Ages eligible
6 Weeks to 8 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy infants aged 6-8 weeks of age ( positive or negative but with no symptoms of current clinical i.e. HIV infection at WHO clinical stage 1);
  • Parents are willing to provide for their child to participate in the study
  • Parents and infant are likely to remain in the study area until the infant is 18 months of age and comply with study requirements including the requirement to return to the same health facility to obtain all other childhood vaccines.

Exclusion criteria

Exclusion Criteria:

  • Infants >8 weeks of age at time of enrolment
  • Signs or symptoms of or infection clinical stage 2 or above.
  • Acute illness (e.g. febrile disease) on the day of vaccination
  • precluding vaccination (e.g. to any component of the vaccine, including diphtheria toxoid)
  • Previous PCV vaccination
  • Family are planning to migrate out of the study areas before the end of the study follow-up
  • Family are planning to obtain the subsequent vaccine doses of the routine immunisation schedule elsewhere and therefore their child may receive a full dose under the routine vaccination programme.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2,100 participants (actual)

Study arms

  • Active comparator
    Full dose PCV13 (2p+1 schedule)

    Full dose PCV13 administration in 2p+1 schedule

    Biological: PCV13

  • Experimental
    40% dose PCV13 (2p+1 schedule)

    Fractional (40%) dose PCV13 administration in 2p+1 schedule

    Biological: PCV13

  • Experimental
    20% dose PCV13 (2p+1 schedule)

    Fractional (20%) dose PCV13 administration in 2p+1 schedule

    Biological: PCV13

  • Active comparator
    Full dose PCV10 (2p+1 schedule)

    Full dose PCV10 administration in 2p+1 schedule

    Biological: PCV10

  • Experimental
    40% dose PCV10 (2p+1 schedule)

    Fractional (40%) dose PCV10 administration in 2p+1 schedule

    Biological: PCV10

  • Experimental
    20% dose PCV10 (2p+1 schedule)

    Fractional (20%) dose PCV10 administration in 2p+1 schedule

    Biological: PCV10

  • Active comparator
    Full dose PCV10 (3p+0 schedule)

    The current vaccine (PCV10) and schedule (3p+0) in use in the Kenyan routine immunisation programme as an additional comparison arm.

    Biological: PCV10

Interventions

  • BiologicalPCV10

    Experimental arms will receive a lower dose of the intervention than the marketed dose.

    Also known as: Synflorix (GlaxoSmithKline plc.), 10-valent pneumococcal conjugate vaccine

  • BiologicalPCV13

    Experimental arms will receive a lower dose of the intervention than the marketed dose.

    Also known as: Prevnar 13 (Pfizer Inc.), 13-valent pneumococcal conjugate vaccine, Prevnar13

06

What researchers measure

Primary outcomes

  1. Immunogenicity: The ratio of IgG GMCs at 1-month post boost

    The ratio of the geometric mean concentrations of IgG after vaccination with 3 full or fractional doses of PCV

    Time frame: 4-weeks post-boost (approximately 10 months of age)

Secondary outcomes

  1. Immunogenicity: the proportion of children who 'seroconvert' to vaccine-serotypes after vaccination

    The proportion of children with vaccine-serotype specific IgG antibody concentrations more than or equal to 0.35 mcg/ml after vaccination

    Time frame: 4-weeks post-primary series (approximately 18 weeks of age)

  2. The proportion of children with evidence of vaccine-serotype carriage

    Vaccine-type carriage prevalence across arms

    Time frame: Approximately 18 months of age

  3. The proportion of children with evidence of vaccine-serotype carriage

    Vaccine-type carriage prevalents across arms

    Time frame: Approximately 9 months of age

  4. The direct vaccine effectiveness of full/fractional doses of PCV13 against carriage of serotypes 6A and 19A

    The direct effectiveness of full/fractional doses of PCV13 in preventing carriage of serotypes 6A and 19A compared to that of full dose PCV10

    Time frame: Approximately 18 months of age

  5. Opsonophagocytic activity of vaccine-induced antibody to 4 serotypes

    Functionality of the antibody response

    Time frame: Approximately 18 months of age

Other outcomes

  1. Immunogenicity: the geometric mean concentration (GMC) of serotype-specific IgG

    IgG GMCs elicited post-primary series

    Time frame: 4-weeks post-primary series (approximately 18 weeks of age)

  2. Safety: the prevalence of adverse events following immunisation by arm

    The proportion fo children with adverse events following immunisation by arm

    Time frame: Infants 6weeks-18 months of age

  3. Immunogenicity: The geometric mean concentration (GMC) of serotype-specific IgG after the primary series of the 2p+1 schedule, prior to boost (9 months of age) and at the end of study follow-up at 18 months of age.

    IgG GMCs at 9 and 18 months of age

    Time frame: Approximately 9 and 18 months of age

07

Study locations

1 site
  • KEMRI Wellcome Trust Research Programme
    Kilifi, Kenya
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data will be open access and held in the LSHTM data repository (http://datacompass.lshtm.ac.uk/cgi/request_doc?docid=1); Data access will be granted upon reasonable request after the primary analyses of the trial, as specified, are published.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After the primary analyses of the trial are published

Access criteria: Upon reasonable request with pre-specified hypothesis

Data sharing details ↗ · datacompass.lshtm.ac.uk

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Sep 2022, 42 months.

Of 21 phase 4 interventional studies under Pneumococcal Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 44. This study's 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2018
First posted
Nov 21, 2018
StartActual
Mar 21, 2019
Primary completionActual
Sep 30, 2022
CompletionActual
Nov 1, 2024
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03489018
Collaborators
University College, London, KEMRI-Wellcome Trust Collaborative Research Program, Bill and Melinda Gates Foundation, National Institute of Health Research (NIHR) Mucosal Pathogens Research Unit (MPRU), Wellcome Trust
Responsible party
Sponsor
First posted
Nov 21, 2018
Start date
Mar 21, 2019
Primary completion
Sep 30, 2022
Completion
Nov 1, 2024
Last update
Nov 12, 2024

Study contacts

J. Anthony G Scott, DTMH FMedSci
principal investigator · London School of Hygiene & Tropical Medicine, Keppel Street, London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 10-valent pneumococcal conjugate vaccine · 13-valent pneumococcal vaccine

Start the discussion